#USA #Jersey City #Public Offering #WallachBeth Capital #bioAffinity Technologies

WallachBeth Capital's Major Move in Biotechnology

WallachBeth Capital LLC, a prominent player in capital markets and institutional execution services, has recently disclosed the pricing of a public offering of shares for bioAffinity Technologies, Inc. This biotechnology company is dedicated to developing noninvasive tests aimed at early-stage cancer detection. The offering is expected to raise approximately $4.8 million, providing crucial funding for the company as it endeavours to push forward in the fight against cancer.

The public offering includes a total of 1,921,799 shares of common stock, priced at $2.50 per share. Additionally, these shares are accompanied by pre-funded warrants priced at $2.493 each, which give investors the option to purchase additional shares at a minor premium. Investors opting for the pre-funded warrants will have the flexibility to exercise them immediately, allowing them greater control over their investment and minimizing risk as they engage in the biotechnology market.

The expected closing date for this transaction is September 30, 2025, contingent on the fulfillment of standard closing conditions. WallachBeth Capital is acting as the exclusive placement agent for this offering, further solidifying its role as a key player in the financial landscape for biotech firms.

This offering not only signals confidence in bioAffinity's innovative approach to cancer diagnostics but also illustrates WallachBeth Capital's commitment to supporting transformative healthcare solutions. As awareness grows around the importance of early detection in effectively combating cancer, bioAffinity's efforts are timely and crucial.

The funds procured from this public offering are anticipated to assist bioAffinity Technologies in advancing its research and development initiatives, thereby improving the accessibility and efficacy of their testing models. This is particularly relevant given the increasing importance of noninvasive diagnostic techniques in modern medicine.

However, it is important to note that the offering is made under the registration statement on Form S-1 filed with the Securities and Exchange Commission (SEC). According to regulatory standards, this announcement is not an offer to sell or solicit buy offers for shares in jurisdictions where such offerings would be unlawful. Instead, it serves to inform potential investors of the opportunity to engage with an innovative company poised on the cutting edge of biotechnology.

As this sector continues to evolve, investors and stakeholders are advised that certain forward-looking statements have been made regarding this offering and its implications. These include, but are not limited to projections about future financial performance, research advancements, and market opportunities. While WallachBeth Capital and bioAffinity Technologies are optimistic, uncertainties such as market conditions and regulatory approvals can significantly affect the outcomes of these ventures.

Conclusion

The forward motion of bioAffinity Technologies, supported by WallachBeth Capital, represents a pivotal step towards enhanced cancer detection methodologies. This offering has the potential to catalyze significant advancements in the field of oncology, improving patient outcomes through innovative technology. Investors considering participating in this offering should carefully evaluate the risks and opportunities as disclosed in the accompanying prospectus, which will be available upon regulatory approval.

Stay informed as we follow further developments from both WallachBeth Capital and bioAffinity Technologies as they aim to make strides in the healthcare industry, particularly within the realm of cancer diagnostics.